Home » ASPREVA COMPLETES PATIENT ENROLLMENT IN TRIAL FOR CELLCEPT
ASPREVA COMPLETES PATIENT ENROLLMENT IN TRIAL FOR CELLCEPT
Aspreva Pharmaceuticals has completed the enrollment of 176 patients in a Phase
III clinical study to assess the safety and efficacy of mycophenolate mofetil
(MMF or CellCept) to maintain or improve symptom control with reduced corticosteroids
in patients with myasthenia gravis.
The randomized, double-blind, placebo-controlled trial is designed to evaluate
the efficacy and safety of MMF to maintain or improve symptom control with reduced
corticosteroids in patients with myasthenia gravis over a treatment period of
36 weeks. The primary endpoint of responder status in the trial encompasses
both minimal disease activity and low steroid dose. The company expects to complete
the trial in late 2006.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May